NCT03741127: Phase 1: Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
- Active, not recruiting
- Dec 8, 2018
- 1 min read
Updated: Feb 10, 2024
NCT03741127: Phase 1: Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
Recruitment Status: Enrolling by invitation
NCT03741127: Phase 1: Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.
Sponsor
Collaborator
California Institute for Regenerative Medicine (CIRM)
Multiple Locations
ClinicalTrials.gov Identifier: NCT03741127
Official Title: Open Label, Multicenter, Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
First Posted: November 14, 2018
Click here for details on Clinicaltrials.gov
Biological: P-BCMA-101 CAR-T cells
autologous anti-BCMA centyrin-based chimeric antigen receptor-expressing Tscm
autologous P-BCMA-101 CAR-T cells
autologous P-BCMA-101 CARTyrin-T cells
Drug: Rimiducid
Drug: Rimiducid may be administered as indicated
Locations
United States, Arizona
United States, California
United States, Colorado
United States, Illinois
United States, Kansas
United States, Maryland
United States, Michigan
United States, New Jersey
United States, Pennsylvania
United States, Tennessee
United States, Texas